Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 10, Issue 4, Pages 292-298Publisher
SPRINGER
DOI: 10.1007/s11910-010-0113-7
Keywords
Parkinson's disease; Dementia; Epidemiology; Pathology; Diagnosis; Treatment
Categories
Funding
- Teva-Lundbeck
- Orion
- Boehringer-Ingelheim
- GlaxoSmithKline
- Novartis
- Eisai
- UCB
- GE
- Michael J. Fox Foundation
Ask authors/readers for more resources
Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality. Over the past decade, increasing research efforts and funding have been directed toward an improved understanding of PDD. Despite these efforts, fundamental gaps remain in our knowledge. Consequently, therapeutic progress has been frustratingly slow and incomplete. To significantly affect PDD, novel disease-modifying agents, rather than more traditional neurotransmitter replacement approaches, likely will be required.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available